Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2025)

Rani Therapeutics Holdings has reported Cash from Operations over the past 6 years, most recently at 308000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 308000.0 for Q4 2025, up 103.56% from a year ago — trailing twelve months through Dec 2025 was 18700000.0 (up 47.32% YoY), and the annual figure for FY2025 was 18700000.0, up 47.32%.
  • Cash from Operations for Q4 2025 was 308000.0 at Rani Therapeutics Holdings, up from 5063000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for RANI hit a ceiling of 308000.0 in Q4 2025 and a floor of 14629000.0 in Q4 2022.
  • Median Cash from Operations over the past 5 years was 9381000.0 (2022), compared with a mean of 9209600.0.
  • Biggest five-year swings in Cash from Operations: crashed 1759.7% in 2021 and later soared 103.56% in 2025.
  • Rani Therapeutics Holdings' Cash from Operations stood at 11449000.0 in 2021, then dropped by 27.78% to 14629000.0 in 2022, then rose by 14.7% to 12478000.0 in 2023, then surged by 30.64% to 8655000.0 in 2024, then surged by 103.56% to 308000.0 in 2025.
  • The last three reported values for Cash from Operations were 308000.0 (Q4 2025), 5063000.0 (Q3 2025), and 5796000.0 (Q2 2025) per Business Quant data.